Mannkind (MNKD) Change in Receivables (2015 - 2026)
Mannkind (MNKD) reported Change in Receivables of -$10.3 million for Q1 2026, down 160.19% year-over-year from $17.1 million in Q1 2025, and down 1159.49% quarter-over-quarter from -$817000.0 in Q4 2025.
Mannkind (MNKD) Change in Receivables (2015 - 2026) Analysis & Trends
Mannkind (MNKD) has 12 years of Change in Receivables data on file, last reported at -$10.3 million in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$10.3 million, down 160.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.6 million (down 351.71% YoY), and the FY2025 annual result was $4.8 million, up 279.56% from the prior year.
- Change in Receivables retreated to -$10.3 million in Q1 2026 per MNKD's latest filing, from -$817000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $17.1 million in Q1 2025 and troughed at -$10.3 million in Q1 2026.
- A 5-year average of $75411.8 and a median of -$817000.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables surged 848.68% in 2022, then sank 170.51% in 2023.
- A 5-year view of Change in Receivables shows it stood at -$6.7 million in 2022, then slipped by 10.07% to -$7.4 million in 2023, then gained by 13.39% to -$6.4 million in 2024, then surged by 87.19% to -$817000.0 in 2025, then sank by 1159.49% to -$10.3 million in 2026.
- Business Quant data shows MNKD's Change in Receivables at -$10.3 million in Q1 2026, -$817000.0 in Q4 2025, and -$9.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | -10.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.29 Mn |
| Mar 31, 2026 | -10.29 Mn |
| Dec 31, 2025 | -817,000.00 |
| Dec 31, 2025 | -817,000.00 |
| Sep 30, 2025 | -9.76 Mn |
| Sep 30, 2025 | -9.76 Mn |
| Jun 30, 2025 | -1.76 Mn |
| Jun 30, 2025 | -1.76 Mn |
| Mar 31, 2025 | 17.10 Mn |
| Mar 31, 2025 | 17.10 Mn |
| Dec 31, 2024 | -6.38 Mn |
| Dec 31, 2024 | -6.38 Mn |
| Sep 30, 2024 | -5.16 Mn |
| Sep 30, 2024 | -5.16 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Mar 31, 2024 | 5.46 Mn |
| Mar 31, 2024 | 5.46 Mn |
| Dec 31, 2023 | -7.37 Mn |
| Dec 31, 2023 | -7.37 Mn |